Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07251387
Recruiting Not applicable

Muscle Synergies in Pain and Pain Anticipation

NCT07251387 · tracked via the Priya Life Science Canada tracker
Sponsor
Universite de Picardie Jules Verne
Phase
Not applicable
Started
2026-01-01
Last updated
2026-06-11

Condition(s) studied

PainNocebo EffectPain Anticipation

Investigational drug(s) / intervention(s)

Pain expectation conditioningGait assesment

Pain expectation conditioning: Participants receive a neutral cream with no real harmful effects with verbal and behavioral suggestions that it may cause localized pain. Researchers wear gloves during application and emphasize the potential discomfort, stating effects may intensify with movement.

Gait assesment: Gait will be assessed both before and after cream application. Each assessment will consist of walking on a treadmill at varying speeds while physiological data (EMG) is recorded. Identical questionnaires (VAS, TAMPA, and PCS) will be administered immediately following the first gait assessment.

Study summary

This study investigates how the anticipation of pain affects muscle synergies. One group will be recruited who will first experience actual pain from capsaicin cream and are then presented with a harmless cream deceptively labeled as capsaicin. The changes in muscle synergies will be measured during walking tasks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18-35 years old * Healthy participant with no self-reported diagnosed neurological, musculoskeletal, or cardiovascular disorders * Body Mass Index (BMI) \< 30 * Ability to walk unaided for at least 10 minutes without major physical limitations Exclusion Criteria: * Presence of pain at the time of testing * Self-reported diagnosed condition affecting mobility * Known allergy to any component of the study cream * Allergy to EMG electrode adhesives * Inability to stand unassisted for more than 1 minute * Inability to walk/run at the required speed and distance * Weight exceeding 150 kg (due to treadmill limitations) * Recent intake (prior intervention) of: * Analgesics (within 6 hours) * Cigarettes (within 6 hours) * Caffeine (within 2 hours) * Skin lesions at the cream application site * Pregnancy * Failure to understand instructions * Daytime pain reported by participant on day of experimentation

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre de Recherche sur le Vieillissement Sherbrooke Canada Recruiting
Université de Picardie Jules Verne Amiens France Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07251387 on ClinicalTrials.gov ↗ ← All trials in Canada